18 May 2017 
EMA/309096/2017 
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (initial authorisation) 
Reagila 
cariprazine 
On 18 May 2017, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive 
opinion, recommending the granting of a marketing authorisation for the medicinal product Reagila, 
intended for the treatment of schizophrenia. The applicant for this medicinal product is Gedeon Richter. 
Reagila will be available as 1.5 mg, 3 mg, 4.5 mg and 6 mg hard capsules. The active substance of 
Reagila is cariprazine, an antipsychotic (ATC code: N05AX15). Cariprazine binds primarily to dopamine D3 
and D2 receptors and serotonin 5-HT1A receptors. 
The benefits with Reagila are its ability to improve psychotic symptoms. The most common side effects 
are akathisia and parkinsonism.  
The full indication is: “Reagila is indicated for the treatment of schizophrenia in adult patients."  
Detailed recommendations for the use of this product will be described in the summary of product 
characteristics (SmPC), which will be published in the European public assessment report (EPAR) and 
made available in all official European Union languages after the marketing authorisation has been 
granted by the European Commission. 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 
days from adoption of the opinion 
30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom 
Telephone  +44 (0)20 3660 6000  Facsimile +44 (0)20 3660 5520 
Send a question via our website www.ema.europa.eu/contact 
An agency of the European Union   
© European Medicines Agency, 2017. Reproduction is authorised provided the source is acknowledged. 
 
  
 
 
 
  
                                                
